Cerus Corporation has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the therapy regimen. Cerus’ research group collaborators include the California Department of Public Health, the University of California, Irvine’s Vaccine Development Research Laboratory, the Vitalant Research Institute, the California National Primate Research Center, and Enable Biosciences. 

Read the press release >


May 29, 2020

Everything Old is New Again:  Powerful Not-So-New Tool for the Battle Against COVID-19



Safety and Sustainability

We are focused on ensuring the safety of our team 

and our stakeholders as we endeavor to achieve our mission 
 establishing INTERCEPT as the global standard of care


In the face of the current COVID-19 pandemic, we have implemented actions to:

>  Ensure the safety of our employees and their families

 Sustain continuity of our supply chain to support current and anticipated demand

    for our products

>  Engage with regulatory authorities, blood centers, and national transfusion

    services to expand availability of the platelet supply

>  Study the efficacy of INTERCEPT against SARS-CoV-2

>  Support blood centers evaluating the use of Convalescent Plasma



    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600